Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of technology-enabled generic drugs, re-engineered drugs and novel drug candidates.
Spotlight
Momenta Pharmaceuticals Reports Financial Results
for the First Quarter of 2008
CAMBRIDGE, MA — May 7, 2008 — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2008.
Momenta Featured in The New England Journal of Medicine
Read the article published online April 23, 2008 on the The New England Journal of Medicine website – “Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System”.
Click Here to Read the Article »
Momenta Featured in Nature Biotechnology
Read the article published online April 23, 2008 on the Nature Biotechnology website - "Oversulfated chondroitin sulfate is a contaminant in
heparin associated with adverse clinical events"
Click Here to Read the Article »
Momenta Featured in Nature
Read the article in the September 20, 2007 issue of Nature featuring Momenta Pharmaceuticals – “The Same but Different”.
Click Here to Read the Article »
FileOpen Plug-in for Adobe Acrobat/Reader required
Competitive Advantage
Momenta's unique business model creates near-term revenue opportunities that will fund longer-term discovery and development efforts. More »
